---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000023"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:35:07.989685+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbbVie revises FY 2025 adj. EPS guidance down $0.13 on $248M IPR&D charge

## Summary
- Q1 2025 includes $248M pre-tax acquired IPR&D and milestones expense.
- Q1 2025 adjusted diluted EPS guidance: $2.34-$2.38 (prior $2.47-$2.51).
- Full-year 2025 adjusted diluted EPS guidance: $11.99-$12.19 (from $12.12-$12.32).
- Revised guidance excludes AbbVie-Gubra GUB014295 licensing deal closed after Q1.
- Company does not forecast future IPR&D milestones due to uncertainty.

## SEC filing metadata
- accession: 0001551152-25-000023
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000023/0001551152-25-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000023/abbv-20250403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000023
- JSON: https://secwatch.observer/filing/0001551152-25-000023.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000023.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.